An observational study in Dialysis; Complications, Central Vein Obstruction and Stenosis, sponsored by Cardionovum GmbH. Terminated at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Cardionovum GmbH · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Constriction, Pathologic with a site in Germany — 6 open to participants now, 8 under way, none of them phase 3. Constriction, Pathologic · Germany.
Among the 43 studies in Constriction, Pathologic with a site in Germany, this one is the 20th largest by enrollment of the 20 observational ones that give a count, is one of 6 that started in 2021, is one of 20 observational ones, and was the 29th registered.
457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.
Browse Constriction, Pathologic studies →6 of the 43 studies in Constriction, Pathologic with a site in Germany are open now. Recruiting first, the newest first:
Phenox GmbH · Sites in Germany, France, Italy and 2 more countries
Insel Gruppe AG, University Hospital Bern · Sites in Germany, Switzerland
Ages 18+
JOTEC GmbH · Sites in Germany
Ages 18+
ZygoFix · Sites in Germany, Italy
Ages 18–75
University Hospital Tuebingen · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 6 started in 2021.
This study's enrollment of 6 is below the median of 84 across 144 observational studies indexed under Constriction, Pathologic.
Median enrollment 70 across the 23 interventional studies, 122 across the 20 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Cardionovum GmbH is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Cardionovum GmbH has 1 study filed under Constriction, Pathologic — fewer than ten, so there is no comparison to draw.
1 of the studies in Constriction, Pathologic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05149755Medtronic CardiovascularEvolut™ EXPAND TAVR II Pivotal Trial | 2027-09 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Constriction, Pathologic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Prospective Observational Single Arm study aimed to assess safety and effectiveness of APERTO OTW DCB in treating stenosis and restenosis of central veins in dialysis patients
The APERTO CVS PMCF study is aimed to evaluate safety and effectiveness of treatment of central veins (re)stenosis in dialysis patients at short and mid-term follow up, after treatment with APERTO OTW DCB. Primary endpoint will consist in evaluating the intervention free period for patients treated with APERTO OTW.
APERTO CVS PMCF Study will also collect data for post-market clinical follow up (PMCF) in a CE mark device used according to intended use
Dialysis patients with symptoms for stenosis or restenosis of central veins to be treated with percutaneous angioplasty.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dialysis patients treated with APERTO OTW following (re)stenosis of central veins
Device: APERTO OTW DCB
Drug Coated Balloon Angioplasty
Clinically Assessed Intervention free period at 6 months fup
clinically assessed intervention free period at 6 months (IFP) defined as dialysis access circuit with no need for clinically driven target lesion repeat intervention for symptom recurrence
Time frame: 6 months
Procedural Technical Success
Residual stenosis is no more than 30% after treatment with APERTO OTW measured by angiography
Time frame: intraoperative
Procedural Clinical Success
After the procedure, haemodialysis access function improved, dialysis function restored, and at least one dialysis session completed
Time frame: intraoperative
Procedural Surgical Success
On the basis of technical success, no major adverse events (MAE) occurred during hospitalization or treatment
Time frame: intraoperative
Major Adverse Event
include death, stroke, thrombosis, allergic reactions, and pulmonary diseases (including pulmonary edema), bleeding complication with the need of transfusion
Time frame: 12 months follow up
Fistula Flow
Flow measured with Echo Doppler measured at 6 months
Time frame: 6 months
Recirculation Rate
Recirculation rate measured at 6 months
Time frame: 6 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2021 to primary completion in Dec 2023, 34 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardionovum GmbH